December 11, 2017 07:00 AM ESTUpdated 09:40 AM
Bioregnum
R&D
Opinion

Can GSK’s new R&D strat­e­gy re­sus­ci­tate the worst per­former in Big Phar­ma?

Bioreg­num
The view from John Car­roll

The new phar­ma chief at GSK is lay­ing out their new pipeline game plan, which should be­gin …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

Judge halts some NIH cuts af­ter 22 states sue

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times